Extracorporeal techniques in radioimmunotherapy

Radioimmunotherapy of Cancer

Volumn , Issue , 2000, Pages 223-243

  Strand, Sven Erik ^a   Sjögren, Hans Olov ^a   Chen, JianQing ^a   Hindorf, Cecilia ^a   Tennvall, Jan G ^b   Garkavij, Michael ^b   Nilsson, Rune ^c   Sandberg, Bengt E B ^c  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c Mitra Medical AB   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 5144225459     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (46)

1. Schreiber GJ, Kerr DE. Strategies to enhance the localization of anticancer immunoconjugates. Curr Med Chem 1995; 2:616-629.
2. Wahl RL, Piko CR, Beers BA, Geatti O, Johnson J, Sherman P. Systemic perfusion: a method of enhancing relative tumor uptake of radiolabeled monoclonal antibodies. J Nucl Med 1987; 28:715.
3. Wahl RL, Piko CR, Beers BA, Geatti O, Johnson J, Sherman P. Systemic perfusion: a method of enhancing reative tumor uptake of radiolabeled monoclonal antibodies. Nucl Med Biol 1988; 15:611-616.
4. Maddock SW, Maddock EN, Quittner SF, Hamstra A, Pastusiak H. Immunoadsorption of circulating monoclonal antibody. In: 7th International Congress of Immunology. New York: Gustav Fisher Verlag, 1989:771.
5. Strand S, Norrgren K, Ingvar C, Erlandsson K, Persson EC. Plasmapheresis as a tool for enhancing contrast in radioimmunoimaging and modifying absorbed doses in radioimmunotherapy. Med Phys 1989; 16:465. Abstract.
6. Bygren P, Freiburghaus C, Lindholm T, Simonsen O, Thysell H, Wieslander J. Goodpasture’s syndrome treated with staphylococcal protein-A immunoadsorption. Lancet 1985:1295-1296.
7. Palmer A, Taube DH, Welsh K, Bewick M, Gjorstrup P, Thick M. Removal of anti-HLA antibodies by extracorporeal immunoadsorption to enable renal transplantation. Lancet 1989:10-12.
8. du Moulin A. LDL immunoapheresis technique. In: Gotto AM, Mancini M, Richter WO, Schwandt P, eds. Treatment of Severe Hypercholeserolemia in the Prevention of Coronary Heart Disease. Basel: Karger, 1990:170-174.
9. Lear JL, Kasliwal RK, Feyerabend AJ, Pratt JP, Bunn PA, Dienhart DG, Gonzales R, Johnson TK, Bloedow DC, Maddock SW, Glenn SD. Improved tumor imaging with radiolabeled monoclonal antibodies by plasma clearance of unbound antibody with anti-antibody column. Radiology 1991; 179:509-512.
10. Dillman RO. Human antimouse and antiglobulin responses to monoclonal antibodies. Antibody Immunoconj Radiopharm 1990; 3:1-9.
11. Riechmann L, Clark M, Waldmann H. Reshaping human antibody for therapy. Nature 1988; 332:323-327.
12. Norrgren K, Strand S, Nilsson R, Lindgren L, Sjögren H. A general extracorporeal immunoadsorption method to increase tumor-to-normal tissue ratio in radioimmunoimaging and radioimmunotherapy. J Nucl Med 1993; 34:448-454.
13. Norrgren K, Strand S, Nilsson R, Lindgren L, Lilliehorn P. Evaluation of extracorporeal immunoadsorption for reduction of the blood background in diagnostic and therapeutic applications of radiolabeled monoclonal antibodies. Antibody Immunoconj Radiopharm 1991; 4:907-914.
14. Breitz HB, Weiden PL, Vanderheyden J, Appelbaum JW, Bjorn MJ, Fer MF, Wolf SB, Ratliff BA, Seiler CA, Foisie DC, Fisher DR, Schroff RW, Fritzberg AR, Abrams PG. Clinical experience with rhenium-186-labeled monoclonal antibodies for radioimmunotherapy: results of phase I trials. J Nucl Med 1992; 33:1099-1112.
15. Camera L, Kinuya S, Garmestani K, Brechbiel MW, Wu C, Pai LH, McCurry TJ, Gansow OA, Pastan I, Paik CH, Carrasquillo JA. Comparative biodistribution of indium and yttrium-labeled B3 monoclonal antibody conjugated to either 1B4MDTPA or 2B-DOTA. Eur J Nucl Med 1994; 21:640-646.
16. Schuster JM, Garg PK, Bigner DD, Zalutsky MR. Improved therapeutic efficacy of a monoclonal antibody radioiodinated using N-succinimidyl 3-(tri-n-butylstannyl) benzoate. Cancer Res 1991; 51:4164-4169.
17. Srivastava SC. Criteria for the selection of radionuclides for targeting nuclear antigens for cancer radioimmunotherapy. Cancer Biother Radiopharm 1996; 11:43-50.
18. Garkavij M, Tennvall J, Strand S, Norrgren K, Lindgren L, Nilsson R, Sjögren H. Enhanced radioimmunotargeting of 125I-L6-biotin monoclonal antibody (MAb) by combining preload of cold L6 MAb and subsequent immunoadsorption. Cancer Res 1995; 12:5874-5880.
19. Paganelli G, Stella M, Zito F, Magnani P, De Nardi P, Mangili F, Baratti D, Veglia F, Di Carlo V, Siccardi AG, Fazio F. Radioimmunoguided surgery using iodine-125-labeled biotinylated monoclonal antibodies and cold avidin. J Nucl Med 1994; 35:1970-1975.
20. Chen JQ, Strand S, Sjögren HO. Optimization of radioiodination and biotinylation of monoclonal antibody chimeric BR96: an indirect labeling using N-succinimidyl-3-(tri-n-butylstannyl)benzoate conjugate. Cancer Biother Radiopharm. 1996; 11: 217-226.
21. Chen JQ, Strand S, Isaksson M, Ljunggren K, Sjögreen K, Garkavij M, Tennvall J, Sjögren H. Biodistribution and pharmacokinetics of 125-I/131-I pair-labeled, biotinylated chimeric BR96 in colon carcinoma isografted rats. Tumor Targeting 1996; 2:204-214.
22. Chen JQ, Strand S, Brechbiel MW, Gansow OA, Sjögren HO. Combination of biotinylation and indium-111 labeling with chelate SCN-Bz-CHX-A-DTPA for chimeric BR96: biodistribution and pharmacokinetic studies in colon carcinoma isografted rats. Tumor Targeting 1996; 2:66-75.
23. Chen JQ, Strand S, Tennvall J, Hindorf C, Sjögren H. Biodistribution and pharmacokinetics of biotinylated 188Re-chiBR96 in colon carcinoma isografted rats. Tumor Targeting 1998; 3:87-95.
24. Mock DM, Malik MI. Distribution of biotin in human plasma: most of the biotin is not bound to protein. Am J Clin Nutr 1992; 56:427-432.
25. Heard GS, Grier RE, Weiner DL, Secor McVoy JR, Wolf B. Biotinidase-possible mechanism for the recycling of biotin. Ann NY Acad Sci 1985; 447:400.
26. Wolf SB, Hymes J, Heard GS. Biotinidase. Methods Enzymol 1990; 184:103-111.
27. DeNardo GL, Maddock SW, Sgouros G, Scheibe PO, DeNardo SJ. Immunoadsorption: an enhancement strategy for radioimmunotherapy. J Nucl Med 1993; 34:1020-1027.
28. Loevinger R, Budinger TF, Watson EE. In: MIRD Primer for Absorbed Dose Calculations. New York: Society of Nuclear Medicine, MIRD, 1991.
29. Johnson TK, Maddock SW, Kasliwal R, Bloedow DC, Hartmann C, Feyerabend A, Dienhart DG, Thickman D, Glenn S, Gonzales R, Lear J, Bunn PA. Radioimmunoadsorption of KC-4G3 antibody in peripheral blood: implications for radioimmunotherapy. Antibody Immunoconj Radiopharm 1991; 4:885-893.
30. Dienhart DG, Kasliwal R, Lear JL, Johnson TK, Bloedow DC, Hartmann C, Seligman PA, Miller GJ, Glenn SD, McAteer MJ, Thickman D, Feyerabend A, Maddock EN, Maddock SW, Bunn PA. Extracorporeal immunoadsorption of radiolabeled monoclonal antibody: a method for reduction of background radioactivity and its potential role during the radioimmunotherapy of cancer. Antibody Immunoconj Radiopharm 1994; 7:225-252.
31. Schindhelm K. Transport and kinetics in synthetic and immunospecific adsorption columns. Artif Organs 1989; 13:21-27.
32. Sgouros G. Plasmapheresis in radioimmunotherapy of micrometastases: a mathematical modeling and dosimetrical analysis. J Nucl Med 1992; 33:2167-2179.
33. Norrgren K, Strand S, Ingvar C. Contrast enhancement in RII and modification of the therapeutic ratio in RIT: a theoretical evaluation of simulated extracorporeal immunoadsorption. Antibody Immunoconj Radiopharm 1992; 5:61-73.
34. Hartmann C, Bloedow DC, Dienhart DG, Kasliwal R, Johnson TK, Gonzales R, Bunn PA. A pharmacokinetic model describing the removal of circulating radiolabeled antibody by extracorporeal immunoadsorption. J Pharm Biopharm 1997; 19: 385-403.
35. Garkavij M, Tennvall J, Norrgren K, Nilsson R, Strand S, Lindgren L, Sjögren H. Improving radioimmunotargeting of tumors: variation in the amounts of MAb L6 combined with an immunoadsorption system. Acta Oncol 1993; 32:853-859.
36. Garkavij M, Tennvall J, Strand S, Sjögren H, Chen JQ, Nilsson R, Isaksson M. Extracorporeal whole blood immunoadsorption enhances radioimmunotargeting of 125-I-labeled BR96-biotin monoclonal antibody in syngeneic rat tumor model. J Nucl Med 1997; 38:895-901.
37. Chen JQ, Strand S, Tennvall J, Lindgren L, Hindorf C, Sjögren HO. Extracorporeal immunoadsorption vs. avidin “chase” to enhance tumor-to-normal tissue ratio for biotinylated 188Re-chiBR96. J Nucl Med 1997; 38:1934-1939.
38. DeNardo GL, DeNardo SJ, Maddock SW, Zeiter PC, Maddock EN, Matthews KJ. Efficacy of immunophoresis to reduce myelosuppression in radioimmunotherapy. J Nucl Med 1992; 33:863-864.
39. DeNardo SJ, O’Grady LF, Warhoe KA, Kroger LA, Hellstrom I, Hellstrom KE, Maddock SW, DeNardo GL. Radioimmunotherapy in patients with metastatic breast cancer. J Nucl Med 1992; 33:862-863.
40. Garkavij M, Tennvall J, Strand S, Nilsson R, Chen JQ, Lindgren L, Isaksson M, Eriksson H, Sjögren H. Extracorporeal immunoadsorption (ECIA) from whole-blood based on avidin-biotin concept: evaluation of a new method. Acta Oncol 1996; 53: 309-312.
41. Kaminski MS, Zasadny KR, Francis IR, Fenner MC, Ross CW, Milik AW, Estes J, Tuck M, Regan D, Fisher S, Glenn SD, Wahl RL. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncal 1996; 14:1974-1981.
42. Press OW, Eary JF, Appelbaum FR, Martin PJ, Nelp WB, Glenn S, Fisher DR, Porter B, Matthews DC, Gooley T, Bernstein ID. Phase II trial of 131-I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas. Lancet 1995; 346:336-340.
43. DeNardo GL, DeNardo SJ. Treatment of B-lymphocyte malignancies with 131-ILym-1 and 67CU-2IT-BAT-Lym-1 and opportunities for improvement. In: Goldenberg DM, ed. Cancer Therapy with Radiolabeled Antibodies. Boca Raton, FL: CRC Press, 1995:217-227.
44. Rietmuller G, Schneider-Gedäcke E, Schlimok G, Schmiegel W, Raab R, Höffken K, Gruber R, Pichlmaier H, Hirche H, Pichlmayr R, Buggisch P, Witte J. Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma. Lancet 1994; 343:1177-1183.
45. Buchsbaum DJ, Khazaeli MB, Liu T, Bright S, Richardson K, Jones M, Meredith RF. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131-I-labeled monoclonal antibody CC49. Cancer Res 1995; 55:5881-5887.
46. Meredith RF, Khazaeli MB, Liu T, Plott G, Wheeler RH, Russel C, Colcher D, Schlom J, Schochat D, LoBuglio AF. Dose fractionation of radiolabeled antiodies in patients with metastatic colon cancer. J Nucl Med 1992; 33:1648-1653.